Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
2024年9月5日 - 5:01AM
ビジネスワイヤ（英語）
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company developing novel small molecule therapeutics
to treat unmet needs in immune-mediated diseases, today announced
that Chris Kirk, Co-founder and Chief Executive Officer, will
present a corporate overview at the H.C. Wainwright 26th Annual
Global Investment Conference on Wednesday, September, 11, 2024 at
12:00 pm ET in New York, NY.
A webcast of the presentation will be available on the “Events
& Presentations” section of the Company’s website at
www.kezarlifesciences.com. Following the event, an archived webcast
will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company developing novel small molecule therapeutics to treat unmet
needs in immune-mediated diseases. Zetomipzomib, a selective
immunoproteasome inhibitor, is currently being evaluated in a Phase
2b clinical trial for lupus nephritis and a Phase 2a clinical trial
for autoimmune hepatitis. For more information, visit
www.kezarlifesciences.com, and follow us on LinkedIn, Facebook,
Twitter and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904911170/en/
Investor and Media Contact: Gitanjali Jain Senior Vice
President, Investor Relations and External Affairs Kezar Life
Sciences, Inc. gjain@kezarbio.com
Kezar Life Sciences (NASDAQ:KZR)
過去 株価チャート
から 10 2024 まで 11 2024
Kezar Life Sciences (NASDAQ:KZR)
過去 株価チャート
から 11 2023 まで 11 2024
